Department of Neurology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Department of Neurology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China; Centre for Neuromuscular and Neurological Disorders, University of Western Australia, Perth, WA, Australia; Department of Neurology, Sir Charles Gairdner Hospital, Queen Elizabeth II Medical Centre, Perth, WA, Australia; Institute of Immunology and Infectious Diseases, Murdoch University, Perth, WA, Australia.
J Neuroimmunol. 2020 Nov 15;348:577387. doi: 10.1016/j.jneuroim.2020.577387. Epub 2020 Sep 8.
Neuromyelitis optica spectrum disorder (NMOSD) is a group of severe inflammatory demyelinating disorders of the central nervous system that involves the optic nerve and spinal cord. Currently the therapeutic options for an acute attack in NMOSD are limited and rarely characterized in clinical studies. This review discussed the overall characteristics of acute attack of NMOSD, related risk factor, prognosis and management. Considering the huge unmet needs and the emergence of new therapeutic targets, we also reviewed innovative treatments that might alleviate attack damage, along with the challenges to evaluate new drug for acute attack in NMOSD.
视神经脊髓炎谱系疾病（NMOSD）是一组累及视神经和脊髓的严重中枢神经系统炎症性脱髓鞘疾病。目前 NMOSD 急性发作的治疗选择有限，且在临床研究中很少有特征描述。本综述讨论了 NMOSD 急性发作的总体特征、相关危险因素、预后和管理。鉴于巨大的未满足需求和新治疗靶点的出现，我们还回顾了可能减轻发作损伤的创新治疗方法，以及评估 NMOSD 急性发作新药的挑战。
